AU2001249214A1 - Suppression of vascular disorders by mucosal administration of heat shock protein peptides - Google Patents

Suppression of vascular disorders by mucosal administration of heat shock protein peptides

Info

Publication number
AU2001249214A1
AU2001249214A1 AU2001249214A AU4921401A AU2001249214A1 AU 2001249214 A1 AU2001249214 A1 AU 2001249214A1 AU 2001249214 A AU2001249214 A AU 2001249214A AU 4921401 A AU4921401 A AU 4921401A AU 2001249214 A1 AU2001249214 A1 AU 2001249214A1
Authority
AU
Australia
Prior art keywords
suppression
heat shock
shock protein
vascular disorders
mucosal administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001249214A
Inventor
Peter Libby
Ruth Maron
Howard L. Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of AU2001249214A1 publication Critical patent/AU2001249214A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
AU2001249214A 2000-03-15 2001-03-15 Suppression of vascular disorders by mucosal administration of heat shock protein peptides Abandoned AU2001249214A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18985500P 2000-03-15 2000-03-15
US60189855 2000-03-15
PCT/US2001/008351 WO2001068124A2 (en) 2000-03-15 2001-03-15 Suppression of vascular disorders by mucosal administration of heat shock protein peptides

Publications (1)

Publication Number Publication Date
AU2001249214A1 true AU2001249214A1 (en) 2001-09-24

Family

ID=22699038

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001249214A Abandoned AU2001249214A1 (en) 2000-03-15 2001-03-15 Suppression of vascular disorders by mucosal administration of heat shock protein peptides

Country Status (3)

Country Link
US (1) US6812205B2 (en)
AU (1) AU2001249214A1 (en)
WO (1) WO2001068124A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd Immunological and oral tolerance-inducing composition and use thereof for the prevention and/or for the treatment of atherosclerosis
JP4191997B2 (en) * 2001-01-04 2008-12-03 ヴァスキュラー バイオジェニックス リミテッド Methods of using plaque-related molecules to prevent and treat atherosclerosis and compositions containing plaque-related molecules
US7135453B2 (en) * 2001-08-23 2006-11-14 Arizona Board Of Regents Reagents and methods for smooth muscle therapies
AU2004216241B2 (en) * 2003-02-21 2006-12-14 Arizona Board Of Regents Methods for promoting wound healing and/or reducing scar formation
US7745578B2 (en) * 2003-07-07 2010-06-29 The General Hospital Corporation Fugetactic proteins, compositions and methods of use
WO2006072946A2 (en) * 2005-01-04 2006-07-13 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Hsp60, hsp60 peptides and t cell vaccines for immunomodulation
WO2006109312A2 (en) * 2005-04-15 2006-10-19 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease
SG173369A1 (en) * 2006-07-12 2011-08-29 Univ Arizona Methods for treating and limiting fibrotic disorders and keloids
US20110111023A1 (en) * 2007-09-11 2011-05-12 Kobenhavns Universitet Prevention of type 1 diabetes by administration of gliadin

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3561444A (en) 1968-05-22 1971-02-09 Bio Logics Inc Ultrasonic drug nebulizer
US3948262A (en) 1969-04-01 1976-04-06 Alza Corporation Novel drug delivery device
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3699963A (en) 1969-10-31 1972-10-24 Alza Corp Therapeutic adhesive patch
US3703173A (en) 1970-12-31 1972-11-21 Ted A Dixon Nebulizer and tent assembly
US3944064A (en) 1973-10-26 1976-03-16 Alza Corporation Self-monitored device for releasing agent at functional rate
GB2042888B (en) 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
US4309406A (en) 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
SE8206744D0 (en) 1982-11-26 1982-11-26 Fluidcarbon International Ab PREPARATION FOR CONTROLLED RELEASE OF SUBSTANCES
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4704295A (en) 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US4615697A (en) 1983-11-14 1986-10-07 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
US4624251A (en) 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
US4635627A (en) 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
US4895724A (en) 1985-06-07 1990-01-23 Pfizer Inc. Chitosan compositions for controlled and prolonged release of macromolecules
GB8514665D0 (en) 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
NZ217844A (en) 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
ATE71287T1 (en) 1986-06-13 1992-01-15 Alza Corp ACTIVATION OF A TRANSDERMAL DRUG DELIVERY SYSTEM BY MOISTURE.
US4713243A (en) 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
US5371109A (en) 1986-07-01 1994-12-06 Drilletten Ab Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
US4838862A (en) 1986-08-04 1989-06-13 Pharmetrix Corp. Portable controlled release osmotic infusion device
US4976958A (en) 1987-02-26 1990-12-11 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
US5641474A (en) 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
ATE258065T1 (en) 1987-06-24 2004-02-15 Brigham & Womens Hospital TREATMENT OF AUTOIMMUNE DISEASES BY ORAL ADMINISTRATION OF AUTOANTIGENS
US5849298A (en) 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5869054A (en) 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5110597A (en) 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US4917895A (en) 1987-11-02 1990-04-17 Alza Corporation Transdermal drug delivery device
US4837027A (en) 1987-11-09 1989-06-06 Alza Corporation Transdermal drug delivery device
NL8703107A (en) 1987-12-22 1989-07-17 Nederlanden Staat POLYPEPTIDES AND DERIVATIVES THEREOF, AND THEIR USE THEREOF IN PHARMACEUTICAL AND DIAGNOSTIC PREPARATIONS.
ATE90570T1 (en) 1988-01-29 1993-07-15 Sumitomo Pharma IMPROVED CONTROLLED DELIVERY FORMULATIONS.
US4898582A (en) 1988-08-09 1990-02-06 Pharmetrix Corporation Portable infusion device assembly
US5296236A (en) 1988-09-16 1994-03-22 Recordati S.A., Chemical And Pharmaceutical Company Controlled release therapeutic system for a liquid pharmaceutical formulations
US5578303A (en) * 1989-03-14 1996-11-26 Yeda Research And Development Co. Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
DK0482089T3 (en) 1989-07-14 1998-05-25 Autoimmune Inc Methods for the treatment of autoimmune uveoretnitis in humans
US5318540A (en) 1990-04-02 1994-06-07 Pharmetrix Corporation Controlled release infusion device
CA2079813A1 (en) * 1990-04-06 1991-10-07 Paul A. Berberian Method of treatment with hsp70
US5257987A (en) 1990-05-21 1993-11-02 Pharmetrix Corporation Controlled release osmotic infusion system
US5416071A (en) 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
IT1250421B (en) 1991-05-30 1995-04-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION WITH BIO-ADHESIVE PROPERTIES.
WO1993010758A1 (en) 1991-12-05 1993-06-10 Pitman-Moore, Inc. A carbohydrate glass matrix for the sustained release of a therapeutic agent
ATE260295T1 (en) 1994-03-21 2004-03-15 Univ Utrecht PEPTIDE FRAGMENTS OF MICROBIAL STRESS PROTEINS AND PHARMACEUTICAL COMPOSITIONS PRODUCED THEREOF FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES
BR9507452A (en) 1994-04-08 1997-08-05 Brigham & Womens Hospital Pharmaceutical composition use of a non-interferon polypeptide use of a quantity of a standardized antigen and a quantity of a non-interferon polypeptide and product containing (1) a quantity of a standardized antigen and (11) a quantity of a non-interferon polypeptide
WO1995027499A1 (en) 1994-04-08 1995-10-19 Brigham And Women's Hospital Treatment of autoimmune disease using oral tolerization and/or type i interferon
IT1271074B (en) 1994-11-21 1997-05-26 Italfarmaco Spa PEPTIDES WITH ANTI-INFLAMMATORY ACTIVITY
US5993803A (en) * 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd Immunological and oral tolerance-inducing composition and use thereof for the prevention and/or for the treatment of atherosclerosis
US6475490B1 (en) * 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins

Also Published As

Publication number Publication date
US6812205B2 (en) 2004-11-02
WO2001068124A3 (en) 2002-03-14
WO2001068124A2 (en) 2001-09-20
US20040192592A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
WO2003033720A8 (en) Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
AU2002305578A1 (en) Applanation tonometer
HK1066468A1 (en) Aqueous sustained-release formulations of proteins
AU2001249214A1 (en) Suppression of vascular disorders by mucosal administration of heat shock protein peptides
AU2001273761A1 (en) Preparation of (r)-2-alkyl-3-phenylpropionic acids
AU7408301A (en) Novel target genes for diseases of the heart
AU1189201A (en) Therapeutic compositions including protein kinase c inhibitors
AU2002300166A1 (en) Process for the Preparation of Peptides
AU2001227960A1 (en) Heat shock/stress protein complexes as vaccines against neurodegenerative disorders
AU2002359026A1 (en) Compositon of dentifrice
AU5667700A (en) Methods to detect protein trafficking disorders
AU2001255168A1 (en) Compositions and methods for the treatment of immune related diseases
AU2002215956A1 (en) Regulation of human pgc-1-like protein
AU2002231620A1 (en) Regulation of human patched-like protein
AU2001268461A1 (en) Uncoupling proteins as targets for the treatment of heart failure
AU2001274446A1 (en) Vip-related peptides for the treatment of skin disorders
AU2001245815A1 (en) Human immune response proteins
AUPR282001A0 (en) Extraction of bioactive proteins
AU2001280460A1 (en) Pulmonary administration of flint
AU2002360333A1 (en) Human angiomotin-like protein 1
AU2002363386A1 (en) Peptide decoys for the preparation of medicaments that are intended for the prevention or treatment of autoimmune pathologies or problems linked to the appearance of antibodies directed against exogenous proteins
AUPQ536800A0 (en) Extraction of bioactive proteins
AU2002217895A1 (en) Inducing expression of heat shock proteins
AU5387299A (en) Dismountable chair consisting of two frames
AU2001263814A1 (en) Regulation of human oatp2-related protein